Search Results
May 30, 2026, 16:57 ET Creality đánh dấu cột mốc 12 năm với KliTek™ và mở rộng hệ sinh thái được hỗ trợ bởi AI
trong lĩnh vực in 3D dành cho người tiêu dùng, đã không ngừng thúc đẩy các công nghệ in 3D dễ tiếp cận, giúp người dùng trên toàn thế giới biến ý tưởng thành các sản phẩm cụ thể. Từ khởi đầu là một nhà sản xuất máy in 3D để bàn, công ty đã phát triển thành một hệ sinh thái sáng tạo 3D dành cho người tiêu
More news about: Creality
May 30, 2026, 16:52 ET 크리얼리티, KliTek™와 AI 기반 생태계 확장으로 12주년 맞아
선전, 중국 2026년 5월 31일 /PRNewswire/ -- 글로벌 소비자용 3D 프린팅 선도 기업 크리얼리티(Creality)는 12년 동안 접근성 높은 3D 프린팅 기술을 발전시키며 전 세계 사용자가 아이디어를 실물 창작물로 구현할 수 있도록 지원해 왔다. 데스크톱 3D 프린터 제조사로 출발한 크리얼리티는 현재 프린터, 스캐너, 레이저 장비, 소재, 소프트웨어 플랫폼, 창작자 커뮤니티를 아우르며 약 140개 국가 및 지역에 걸친 글로벌 소비자용 3D 창작 생태계로 성장했다.
More news about: Creality
May 30, 2026, 16:15 ET AdvisorVault Adds Social Media Archiving to its Consolidated D3P Service
email alerts to compliance officers monitoring activity across social mediaAbout AdvisorVaultAdvisorVault is the only FINRA D3P with a Consolidated 17a-4 Service, designed to give small firms everything needed to meet today's data compliance demands. Our turn-key approach performs
More news about: AdvisorVault
May 30, 2026, 15:25 ET Menarini Group 於 2026 年美國臨床腫瘤學會 (ASCO) 週年大會上發表第 1b/2 期 ELEVATE 研究中，使用埃拉司群 (Elacestrant) 聯合卡帕塞替尼 (Capivasertib) 治療 ER+、HER2- 轉移性乳癌 (mBC) 患者的最新數據。
(capivasertib)）聯合治療的療效。2026 年美國臨床腫瘤學會週年大會上公佈的 ELEVATE 研究結果（摘要 1098）[1] 中，包括來自埃拉司群 (258-345 毫克) 配合卡帕塞替尼 (320-400 毫克) 第 1b 期隊列 (n=31) 的安全性及初步療效數據，這些數據顯示在建議第 2 期劑量 (RP2D) 隊列中，患者展現出初步中位無惡化存活期 (mPFS) 獲益。 在第 2 隊列 (n=9) 中確立的建議第 2 期劑量為埃拉司群 345 毫克，配合卡帕塞替尼 320 毫克，每日兩次（採 4 天用藥／3 天停藥的方式）。在建議第 2 期劑量可評估反應的患者中，初步療效顯示疾病控制率
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 15:19 ET 엔진AI, 선전 지능형 제조 기지 가동하며 1차 T800 휴머노이드 로봇 생산 완료 및 대규모 납품 개시
지능형 생산을 중심으로 한 제조 시스템을 구축함으로써 시범 생산에서 대량 제조로, 제로에서 규모화로 나아가는 여정을 가속했다"고 말했다.타협 없는 품질을 위한 네 가지 전략적 축엔진AI는 풀스택(full-stack) 독자 연구개발(R&D) 역량을 바탕으로 네 가지 전략적 축에 기반한 엄격한 품질 보증 체계를 구축했다.공급망 품질 관리: 통합 조인트부터 전체 조립품에 이르기까지 모든 부품이 엄격한 표준을 충족해 적격 부품만 생산 공정에 투입되도록
More news about: EngineAI
May 30, 2026, 15:15 ET EngineAI Resmikan Pabrik Cerdas di Shenzhen, Robot Humanoid T800 Mulai Dikirim secara Massal
massal, bergerak dari nol menuju skala penuh."Empat Pilar Strategis yang Menjaga KualitasDidukung kemampuan riset dan pengembangan (R&D) secara independen, EngineAI mengembangkan sistem penjaminan mutu yang bertumpu pada empat pilar utama:Kualitas rantai pasok
More news about: EngineAI
May 30, 2026, 14:58 ET Cyient Enters Agreement to Acquire TAO Digital
customers through strong execution and partnership. I am excited about what we will build together."About CyientCyient is a global ER&D company delivering full lifecycle engineering for mission-critical industries, spanning design-to-aftermarket across products, plants, and networks.
More news about: Cyient
May 30, 2026, 14:43 ET Cyient Enters Agreement to Acquire TAO Digital
customers through strong execution and partnership. I am excited about what we will build together."About CyientCyient is a global ER&D company delivering full lifecycle engineering for mission-critical industries, spanning design-to-aftermarket across products, plants, and networks.
More news about: Cyient
May 30, 2026, 11:35 ET /C O R R E C T I O N -- Hyundai Motor America/
headquarters in California, the Hyundai Motor Manufacturing Alabama assembly plant, the all-new Hyundai Motor Group Metaplant America, several cutting-edge R&D facilities and more than 855 independent dealers. These operations are part of Hyundai Motor Group, which is
More news about: Hyundai Motor America
May 30, 2026, 11:18 ET HMS 비전과 원저우 의과대학, 비전 차이나 2026에서 시뮬레이션 기반 교육 센터 확장 발표
content:https://www.prnewswire.com/kr/news-releases/u0068u006Du0073u002DuBE44uC804uACFCu002DuC6D0uC800uC6B0u002DuC758uACFCuB300uD559u002Cu002DuBE44uC804u002DuCC28uC774uB098u002Du0032u0030u0032-302786292.htmlSOURCE
More news about: HMS Vision Inc.
May 30, 2026, 11:06 ET MakerWorld's First User-Initiated Charity Contest Names Winners, Bringing Global Creators' Goodwill Directly to Cancer Wards
focusing on desktop 3D printers. Its state-of-the-art 3D printers offer a feature-rich first-class experience for a global community of 3D printing makers, aiming to break the barriers between the digital and physical worlds and bring creativity to a whole new level. Bambu Lab sells its 3D printers, filaments,
More news about: Bambu Lab
May 30, 2026, 10:19 ET The 7th China-CEEC Local Leaders' Meeting and 2026 Shandong International Friendship Cities Cooperation and Exchange Week Successfully Held
https://mmx.prnewswire.com/media/MS1851022/837a7174d52f43d283adf39cc59ea9c5.jpg
More news about: Shandong International Friendship Cities Cooperation and Exchange Week
May 30, 2026, 09:09 ET Il Gruppo Menarini presenta nuovi dati dello studio ELEVATE di fase 1b/2 su elacestrant in combinazione con capivasertib in pazienti con carcinoma mammario metastatico (mBC) ER+, HER2- in occasione del Congresso annuale 2026 dell'American Society of Clinical Oncology (ASCO)
trattata con la dose raccomandata per la fase 2 (RP2D). La RP2D è stata determinata nella coorte 2 (n=9) come elacestrant 345 mg più capivasertib 320 mg BID (4 giorni di trattamento/3 giorni di pausa).Nei pazienti valutabili per la risposta alla RP2D, l'efficacia preliminare ha mostrato un tasso
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:07 ET Menarini Group apresenta novos dados do estudo ELEVATE de Fase 1b/2 sobre o elacestranto em associação com o capivasertibe em pacientes com câncer de mama metastático (CMm) ER+, HER2- no Congresso Anual de 2026 da American Society of Clinical Oncology (ASCO)
progressão (mPFS) na coorte da dose recomendada para a fase 2 (RP2D). A RP2D foi determinada na coorte 2 (n=9) como sendo 345 mg de elacestranto mais 320 mg de capivasertibe BID (4 dias on/3 dias off).Em pacientes avaliáveis por resposta RP2D, a eficácia preliminar mostrou uma taxa de controle de doença
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:02 ET Menarini Group presenta nuevos datos del ensayo ELEVATE de fase 1b/2 de elacestrant combinado con capivasertib en pacientes con cáncer de mama metastásico (CMM) con receptores de estrógeno positivos (ER+) y HER2 negativo (HER2-) en la reunión anual de la Sociedad Estadounidense de Oncología Clínica (ASCO) de 2026
cohorte de dosis recomendada de fase 2 (RP2D). Se determinó que la RP2D en la cohorte 2 (n=9) era 345 mg de elacestrant más 320 mg de capivasertib dos veces al día (4 días de tratamiento y 3 días de descanso).En los pacientes evaluables por respuesta a RP2D, la eficacia preliminar mostró una tasa
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:00 ET Real Estate Expert Justus Smith of Keystone Explains Where Real Estate Commission Dollars Go for HelloNation
estate commissions also cover specialized services that enhance presentation. Smith mentions that these can include professional staging, drone footage, 3D virtual tours, or digital advertising campaigns. The HelloNation article highlights that such services, often paid for through the agent's commission,
More news about: HelloNation
May 30, 2026, 08:00 ET GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
esophagus, head and neck, liver/bile duct, lung, lymphoma, myeloma/plasma cell neoplasm, ovary, pancreas, stomach.3 Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol.
More news about: GRAIL, Inc.
May 30, 2026, 06:29 ET EngineAI ra mắt cơ sở sản xuất thông minh tại Thâm Quyến, lô robot hình người T800 đầu tiên xuất xưởng, bắt đầu giao hàng quy mô lớn
và từ con số 0 tới quy mô lớn".Bốn trụ cột chiến lược bảo đảm chất lượng toàn diệnTận dụng năng lực nghiên cứu và phát triển (R&D) toàn diện độc lập, EngineAI đã thiết lập một khuôn khổ bảo đảm chất lượng nghiêm ngặt được xây dựng dựa trên bốn trụ cột chiến lược:Kiểm
More news about: EngineAI
May 30, 2026, 06:00 ET MakerWorld's First User-Initiated Charity Contest Names Winners, Bringing Global Creators' Goodwill Directly to Cancer Wards
focusing on desktop 3D printers. Its state-of-the-art 3D printers offer a feature-rich first-class experience for a global community of 3D printing makers, aiming to break the barriers between the digital and physical worlds and bring creativity to a whole new level. Bambu Lab sells its 3D printers, filaments,
More news about: Bambu Lab
May 29, 2026, 23:32 ET The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
by MSD.About Kelun-BiotechKelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major
More news about: Kelun-Biotech
May 29, 2026, 23:29 ET Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
NSCLC.About Kelun-BiotechKelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major
More news about: Kelun-Biotech
May 29, 2026, 19:30 ET LAWSUIT FILED ON BEHALF OF CHILD HOSPITALIZED WITH HEMOLYTIC UREMIC SYNDROME IN THE KEBAB SHOP E. COLI OUTBREAK
LOS ANGELES, May 29, 2026 /PRNewswire/ -- On May 29, 2026, attorneys William D. Marler of Marler Clark, Inc., PS and Trevor Quirk of Quirk Law Firm LLP filed a personal injury lawsuit in Los Angeles County Superior Court on behalf
More news about: Marler Clark, The Food Safety Law Firm
May 29, 2026, 17:31 ET Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
and depth of the innovation across our radiotherapy platform and our commitment to protecting it in every key market," said Adeela Kamal, Ph.D., EVP-R&D of Actinium Pharmaceuticals. "Securing coverage for both our Actimab-A CLAG-M combination in AML and our Iomab-ACT conditioning approach for gene-edited
More news about: Actinium Pharmaceuticals, Inc.
May 29, 2026, 17:06 ET Die Menarini Group präsentiert auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) neue Daten aus der Phase-1b/2-Studie ELEVATE zu Elacestrant in Kombination mit Capivasertib bei Patientinnen mit ER-positivem, HER2-negativem metastasiertem Brustkrebs (mBC)
empfohlenen Phase-2-Dosis (RP2D) belegen. In Kohorte 2 (n = 9) wurde die empfohlene Tagesdosis (RP2D) auf 345 mg Elacestrant plus 320 mg Capivasertib zweimal täglich (4 Tage Einnahme, 3 Tage Pause) festgelegt.Bei den Patienten, bei denen das Ansprechen im Rahmen der RP2D-Studie bewertet werden konnte,
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 16:00 ET ZIEGLER CLOSES $30,750,000 FINANCING FOR LEBANON VALLEY BRETHREN HOME D/B/A LONDONDERRY VILLAGE (PA)
More news about: Ziegler